Clinical Trial Update: MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating MEDI5752 in combination with carboplatin and pemetrexed for unresectable pleural mesothelioma is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pleural Mesothelioma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• MEDI5752
• Pemetrexed (pemetrexed)

Snippet

Sponsor: AstraZeneca | Conditions: Unresectable Pleural Mesothelioma | Phase 3 | Status: ACTIVE_NOT_RECRUITING